Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Immune Design Corp. (IMDZ)

Add IMDZ Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 10/20/2017 3:53:55 PM - Followers: 1 - Board type: Free - Posts Today: 0

Immune Design Corp. 1616 Eastlake Avenue East Suite 310 Seattle, WA 98102 United States Phone: 206-682-0645 Fax: 206-682-0648 Website: Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo immunotherapy treatments. The company develops various product candidates based on its IMDZVex and GLAAS product discovery platforms. Its oncology clinical-stage product candidates include LV305, G305, and CMB305, which are in Phase-I clinical trials for the treatment of solid tumor types, such as breast cancer, melanoma, non-small cell lung cancer, ovarian cancer, or sarcoma. The companys oncology clinical-stage product candidates also comprise G100 that is in Phase-I clinical trials for the treatment of patients with merkel cell carcinoma and sarcoma; and in pre-clinical stage for the treatment of non-Hodgkin lymphoma. It also develops therapies for non-oncology diseases, including infectious diseases, allergy, and autoimmune diseases. The company has license agreements with the California Institute of Technology, University of North Carolina at Chapel Hill, Infectious Disease Research Institute, MedImmune LLC, and Sanofi; collaboration agreements with Sanofi Pasteur, Merck & Co., Inc., and Genentech. Immune Design Corp. was founded in 2008 and is headquartered in Seattle, Washington with additional facilities in South San Francisco, California.
Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IMDZ News: Amended Statement of Changes in Beneficial Ownership (4/a) 10/20/2017 11:51:57 AM
IMDZ News: Immune Design Announces G100’s Receipt of Orphan Drug Designation by the EMA for the Treatment of Follicular Non-Hodgkin’... 10/19/2017 04:05:00 PM
IMDZ News: Current Report Filing (8-k) 10/16/2017 04:34:22 PM
IMDZ News: Immune Design Announces Positive FDA Feedback on Phase 3 Clinical Trial Design for CMB305 in Synovial Sarcoma Patients 10/16/2017 04:15:00 PM
IMDZ News: Statement of Ownership (sc 13g) 10/06/2017 04:16:13 PM
#30   Churning at 5.20 like mad - crazy run QServus 10/20/17 03:53:54 PM
#29   Looks like bottom is in QServus 10/20/17 01:10:13 PM
#28   Break that resistance @ 6 and off to QServus 10/20/17 07:42:30 AM
#27   RBC upper their target on this from $20 QServus 10/19/17 08:46:05 PM
#26   Yea but $6 is almost hitting now after market QServus 10/19/17 04:52:35 PM
#25   Down 6 days in a row -50% shurtha2000 10/19/17 04:50:06 PM
#24   We can definitely close 6.50-7 tomorrow QServus 10/19/17 04:49:13 PM
#23   Yep, why did it drop in first place lol QServus 10/19/17 04:43:45 PM
#22   Stuck at $5.60 AH's should bounce tomorrow shurtha2000 10/19/17 04:33:38 PM
#21   Huge news out we gap up tomorrow wow QServus 10/19/17 04:07:15 PM
#20   I think we'll have a good bounce tomorrow QServus 10/19/17 03:37:17 PM
#19   Why did it drop so quick ? I QServus 10/19/17 03:09:43 PM
#18   I had to get out. Pushed my comfort Bleederhead 10/19/17 02:54:45 PM
#17   What's the scoop why the big drop QServus 10/19/17 02:52:10 PM
#16   Seems like rock bottom opportunity here QServus 10/19/17 02:51:58 PM
#15   I'm in for this upcoming ride. Glta Bleederhead 10/17/17 04:30:21 PM
#14   BROOKSIDE CAPITAL MANAGEMENT LLC has filed a new wiltonio 10/06/17 04:17:37 PM
#13   Immune Design (NASDAQ:IMDZ) initiated with Outperform rating and Avispa 08/24/17 08:16:01 AM
#12   Charts show a move to $22 biotechnician 06/27/17 08:16:57 AM
#11   IMDZ bearish 8.30 stocktrademan 11/13/16 04:31:05 PM
#10   The webcast for the second quarter financial results jondoeuk 08/05/16 06:49:27 AM
#9   (A Phase I should be happening some time jondoeuk 07/10/16 04:46:37 AM
#8   New Corporate Overview jondoeuk 07/10/16 04:45:29 AM
#7   Immune Design Releases New PFS, OS and TME jondoeuk 07/10/16 04:43:39 AM
#6   The two abstracts from this year's ASCO meeting jondoeuk 07/10/16 04:42:28 AM
#5   $11.38 chart looks decent for a swing. RealGenius 03/28/16 10:08:25 PM
#4   Thank you. I will email you a few tickers. That's tpizzazz24 11/28/15 10:27:27 AM
#3   Hi Tpizzazz24, stocktrademan 11/27/15 03:04:27 PM
#2   Thanks for the DD. You do a hell of tpizzazz24 11/27/15 12:17:22 PM
#1   $IMDZ recent news/filings stocktrademan 11/25/15 02:07:04 PM